CYANOTECH CORP
Close on Oct 19, 2026
- Market cap
- $5.11M
- P/E (TTM)
- –
- Dividend yield
- –
About Cyanotech
Medicinal Chemicals & Botanical Products, SIC 2833
Cyanotech Corporation cultivates and manufactures microalgae into natural health and nutritional products. Operating as a single segment, the company develops two main product lines: BioAstin, a natural antioxidant derived from Haematococcus pluvialis microalgae, and Hawaiian Spirulina Pacifica, a nutrient-dense microalgae superfood. These items are produced in formats such as bulk powders, tablets, gelcaps, and gummies. The company also offers contract extraction along with research and development services. Products are distributed directly to consumers, online channels, retailers, and natural product distributors, as well as to dietary supplement manufacturers, health food formulators, and cosmetic manufacturers.
The company conducts its operations at a 96-acre microalgae cultivation and processing facility situated on the Kona Coast of Hawaii. Astaxanthin processing is carried out using high-pressure supercritical carbon dioxide extraction at this Kona site. Cyanotech Corporation maintains its principal executive offices in Kailua-Kona, Hawaii.
Summary of the business section of Cyanotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CYANOTECH CORP
- Founded
- 1983
- Headquarters
- Kailua Kona, HI
- Address
- 73-4460 Queen Kaahumanu Hwy, Suite 102 96740
- Phone
- (808) 326-1353
- Employees
- 83, Mar 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- Nevada
- Fiscal year ends
- March 31
- Auditor
- BPM LLP, Walnut Creek, California
Stock & identifiers
- Ticker
- CYAN
- Exchange
- OTC
- IPO date
- May 21, 1991
- Shares outstanding
- 7M, Nov 1, 2025
- Public float
- $2.98M, Sep 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Nov 6, 2006
- SEC CIK
- 768408
- EIN
- 91-1206026
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Keith Custer | President and CEO, Director | 6,754 |
| Jennifer A.S. Miyashiro | CFO, VP Fin & Admin, Treasurer | – |
| Jennifer M. Johansen | VP, Quality, Regulatory & Govt | 9,743 |
| Glenn Jensen | VP, Operations | 44,320 |
| Amy Beth Nordin | VP, HR, Secretary | 9,051 |
| Jennifer Kimberly Brand | VP of Sales | – |
| Collette Nicole Kakuk | Chief Strategic Comml Officer | 4,721 |
| Michael A. / Davis | Director | 1,838,756 |
| David L. Vied | Director | 225,138 |
| David M. Mulder | Director | 203,468 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $315.18K | $267.29K | $87.71K | $11 | – |
| FY2025 Gerald RCysewski | $48.79K | $45.35K | $87.71K | $11 | – |
| FY2025 Matthew KCuster | $266.39K | $221.94K | $87.71K | $11 | – |
| FY2024 | $322.83K | $248.59K | $160.51K | $9 | – |
| FY2024 Gerald RCysewski | $47.36K | $48.93K | $160.51K | $9 | – |
| FY2024 Matthew KCuster | $275.48K | $199.66K | $160.51K | $9 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2025, we employed 83 people.”
Corporate history
Events identified from SEC filings